Whipple’s Disease Industry Research Insights on Preventive Techniques, Diagnosis and Treatment Overview By Top Key Player Therapeutics and Strategic Assessment Report 2019
Whipple’s disease (WD) is a rare, chronic, systemic infectious bacterial disease caused by Tropheryma whipplei that affects gastrointestinal system, especially, the small intestine. The infection may spread to any part of the body but mostly it affects the central nervous system, joints, lungs, heart, and eyes.
The “global Whipple’s Disease Industry is expected to grow at the CAGR of ~3.1% during the forecast period and is estimated to reach USD 255.3 million by 2023.”
Some common symptoms of this disease are weight loss, diarrhea, abdominal cramping and pain, weakness, fatigue, anemia, inflamed joints, and some other less common symptoms. The prevalence is one in one million people. The prevalence of this diseases is more in men than women.
Competitive Analysis:
Some of the key players in this market are –
- AbbVie Inc. (US)
- Allergan (Republic of Ireland)
- Bayer AG (Germany)
- Bristol-Myers Squibb Company (US)
- Hoffmann-La Roche Ltd. (Switzerland)
- Henry Schein Inc (US)
- Pfizer Inc. (US)
Brows Full detailed Report at https://www.marketresearchfuture.com/reports/whipple-s-disease-market-4094
Intended Audience
- Whipple’s Disease Diagnostic and Treatment Supplies Companies
- Whipple’s Disease Diagnostic and Treatment Supplies Providers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors
Comments
Post a Comment